Skip to main content

Table 10 Relation of TLR4 haplotypes versus demographic, clinical, and outcome data in vitiligo patients

From: TLR4 gene polymorphisms in Egyptian vitiligo patients: insights into emerging association with clinical activity, family history, and response to therapy

   Haplotype
ACC ACT ATC ATT GCC GCT GTC GTT
Sex M/F 0.04/0.09 0.26/0.14 0.04/0.00 0.26/0.25 0.00/0.07 0.17/0.18 0.06/0.07 0.13/0.18
P 0.45 0.14 0.20 0.89 0.12 0.96 1.00 0.96
Course R/P 0.00/0.07 0.50/0.14 0.00/0.02 0.50/0.25 0.00/0.04 0.00/0.20 0.00/0.07 0.00/0.17
P 1.00 0.05 1.00 0.34 1.00 0.59 1.00 0.58
Psychic trauma NO/Yes 0.06/0.07 0.20/0.19 0.01/0.03 0.23/0.34 0.04/0.03 0.21/0.07 0.04/0.15 0.18/0.07
p 1.00 0.91 0.45 0.25 1.00 0.14 0.07 0.23
Alopecia NO/Yes 0.05/0.14 0.19/0.21 0.02/0.00 0.26/0.21 0.04/0.00 0.18/0.14 0.04/0.21 0.17/0.07
p 0.25 1.00 1.00 1.00 1.00 1.00 0.06 0.46
FH vitiligo NO/Yes 0.05/0.25 0.19/0.25 0.02/0.00 0.26/0.25 0.04/0.00 0.18/0.12 0.06/0.12 0.17/0.00
p 0.09 0.65 1.00 1.00 1.00 1.00 0.45 0.35
FHAIDs NO/Yes 0.04/0.33 0.19/0.22 0.02/0.00 0.28/0.00 0.04/0.00 0.19/0.00 0.06/0.11 0.14/0.33
p 0.02 1.00 1.00 0.11 1.00 0.35 0.49 0.15
Remission NO/Yes 0.08/0.06 0.18/0.21 0.00/0.03 0.40/0.17 0.02/0.04 0.16/0.19 0.02/0.09 0.11/0.19
p 0.71 1.00 0.53 0.02 1.00 0.79 0.25 0.39
Type Seg/Non-Seg 0.05/0.07 0.17/0.20 0.00/0.02 0.41/0.22 0.05/0.03 0.11/0.19 0.05/0.07 0.11/0.16
p 1.00 1.00 1.00 0.12 0.53 0.73 1.00 0.73
  1. M/F male/female, R/P regressive/progressive, Seg/Nonseg segmental/nonsegmental, FH family history, FHAIDs family history of auto-immune diseases, p value significant if < 0.05
  2. Fischer exact test
  3. Significant p value between ACC haplotype and family history of AID and between ATT haplotype and remission